| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The molecular targets are β1-, β2-, and α1-adrenergic receptors, with Ki values of approximately 0.9 nM, 2.0 nM, and 12 nM, respectively; it also inhibits lipid peroxidation with an IC50 of approximately 5 µM, and the (S)-enantiomer carries most of the β-blocking activity while both enantiomers contribute to α1-blockade and antioxidant effects.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, carvedilol-d5 competes with radiolabeled β- and α1-adrenergic ligands for recombinant or native receptors, antagonizes isoproterenol-stimulated cAMP accumulation in cardiomyocytes, inhibits phenylephrine-induced vasoconstriction, and inhibits lipid peroxidation with an IC50 of approximately 5 µM; the deuterated form retains receptor blocking and antioxidant activities. |
| ln Vivo |
In vivo, oral carvedilol-d5 reduces heart rate and blood pressure, improves cardiac function and survival in heart failure models, and protects against doxorubicin-induced cardiotoxicity; the labeled form is used to quantify plasma and tissue concentrations and to relate β1/β2/α1 occupancy to hemodynamic and cardioprotective effects.
|
| Enzyme Assay |
Noncellular binding assays incubate membrane homogenates expressing recombinant human β1, β2, or α1 receptors with radiolabeled antagonists ([125I]iodocyanopindolol or [3H]prazosin) and increasing concentrations of carvedilol-d5; Ki values are calculated from displacement curves, and antioxidant activity is measured by inhibition of lipid peroxidation in rat brain homogenate.
|
| Cell Assay |
Cellular functional assays use neonatal rat cardiomyocytes or CHO cells expressing β1/β2 receptors, preincubated with carvedilol-d5 before isoproterenol challenge; cAMP accumulation is measured by enzyme immunoassay, and α1-mediated calcium mobilization is assessed in vascular smooth muscle cells, with cell viability monitored in parallel.
|
| Animal Protocol |
Animal protocols administer carvedilol-d5 orally to rats, mice, or dogs at doses of 0.1–10 mg/kg; heart rate, blood pressure, cardiac function by echocardiography, and survival in heart failure models are measured, and plasma and tissue concentrations are quantified by LC-MS/MS to relate adrenergic receptor occupancy to hemodynamic and cardioprotective effects.
|
| References |
|
| Molecular Formula |
C24H26N2O4
|
|---|---|
| Molecular Weight |
406.47424
|
| Exact Mass |
411.221
|
| CAS # |
929106-58-1
|
| Related CAS # |
Carvedilol;72956-09-3
|
| PubChem CID |
45358932
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.128
|
| tPSA |
75.74
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
30
|
| Complexity |
508
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
|
| InChi Key |
OGHNVEJMJSYVRP-IZIHCQFESA-N
|
| InChi Code |
InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3/i15D2,16D2,17D
|
| Chemical Name |
1-(9H-carbazol-4-yloxy)-1,1,2,3,3-pentadeuterio-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4602 mL | 12.3010 mL | 24.6021 mL | |
| 5 mM | 0.4920 mL | 2.4602 mL | 4.9204 mL | |
| 10 mM | 0.2460 mL | 1.2301 mL | 2.4602 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.